Please login to the form below

Not currently logged in
Email:
Password:

PhRMA appoints new EVP of public affairs

The Pharmaceutical Research and Manufacturers of America has appointed Josephine Martin as executive vice president, public affairs
The Pharmaceutical Research and Manufacturers of America (PhRMA) has appointed Josephine Martin as executive vice president, public affairs, reporting to PhRMA president and CEO John J Castellani, with effect from March 1, 2011. 

Martin, former senior vice president of public affairs at Ketchum, will be responsible for leading and managing PhRMA's communications and alliance development functions. 

Before joining Ketchum, Martin held leading public affairs positions at Golin Harris and National Media, Inc. Her health policy communications experience was developed earlier in her career as senior vice president, public affairs for the Federation of American Hospitals, and vice president of communications at the American Red Cross.

"We are thrilled to have Josie join our team at PhRMA. She brings extensive and successful experience in DC public affairs – with a particular strength in health policy communications," Castellani said. 

Commenting on her appointment, Martin said: "There are few, if any, American industries that positively impact people's lives in so many ways -- from improving health and productivity to providing good jobs, to strengthening local and national economies – as the biopharmaceutical sector." 

"I am excited to join such an energised, impactful organisation as PhRMA, and I relish the chance to bring my experience to bear as we work to best convey the tremendous value of this innovative sector," she continued.

7th February 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics